Estetrol Is Safe and Well Tolerated during Treatment of Hospitalized Men and Women with Moderate COVID-19 in a Randomized, Double-Blind Study

Jean Michel Foidart, Krzysztof Simon, Wulf H Utian, Franck Mauvais-Jarvis, Jonathan Douxfils, Graham Dixon, Philip Barrington

Research output: Contribution to journalArticlepeer-review

27 Downloads (Pure)

Abstract

Epidemiological data suggest that the severe acute respiratory syndrome coronavirus 2 infection rate is higher in women than in men, but the death rate is lower, while women (>50 years) on menopausal hormone therapy (MHT) have a higher survival rate than those not on MHT. Classical oral estrogen enhances the synthesis of coagulation markers and may increase the risk of thromboembolic events that are common in coronavirus disease 2019 (COVID-19). The favorable hemostatic profile of estetrol (E4) might be suitable for use in women who are receiving estrogen treatment and contract COVID-19. A multicenter, randomized, double-blind, placebo-controlled, phase 2 study (NCT04801836) investigated the efficacy, safety, and tolerability of E4 versus placebo in hospitalized patients with moderate COVID-19. Eligible postmenopausal women and men (aged ≥ 18 years old) were randomized to E4 15 mg or placebo, once daily for 21 days, in addition to the standard of care (SoC). The primary efficacy endpoint of improvement in COVID-19 (percentage of patients recovered at day 28) between the placebo and E4 arms was not met. E4 was well tolerated, with no safety signals or thromboembolic events, suggesting that postmenopausal women can safely continue E4-based therapy in cases of moderate COVID-19 managed with SoC.

Original languageEnglish
Article number3928
JournalJournal of clinical medicine
Volume12
Issue number12
DOIs
Publication statusPublished - 8 Jun 2023

Keywords

  • coagulation
  • COVID-19
  • E4
  • estetrol
  • estrogen
  • hospitalization
  • human fetal estrogen
  • postmenopausal
  • thromboembolic events

Fingerprint

Dive into the research topics of 'Estetrol Is Safe and Well Tolerated during Treatment of Hospitalized Men and Women with Moderate COVID-19 in a Randomized, Double-Blind Study'. Together they form a unique fingerprint.

Cite this